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Abstract
Serine proteases play a key function in extracellular processes affecting central nervous system plasticity. Recently, the role of
extracellular proteolytic processes in regulating synaptic structure and function has been described. However, to date direct evidence
linking extracellular serine protease activity with drug-related behavioural changes has not been documented. Importantly, in a
screening for genes induced after drug treatment we found that urokinase plasminogen-type activator (uPA) was strongly regulated
by cocaine in several protocols of drug administration. Cocaine-induced up-regulation could be veriﬁed on microarray analysis under
several protocols of drug administration, then further fully conﬁrmed by means of qRT-PCR. As a result, we chose to investigate
further uPA function in the mesolimbic dopaminergic pathway, a major target area of cocaine and drugs of misuse. Our approach was
based on the characterization of cocaine-induced behavioural changes following lentiviral vector delivery of a doxycycline-regulated
uPA expression cassette (or of its mutated form), into speciﬁc rat brain areas (the hippocampus, the nucleus accumbens and the
ventral tegmental area). We show that doxycycline-dependent over-expression of uPA in these regions yields a 10- to 12.3-fold
increase in locomotor activity after cocaine administration. These behavioural effects were completely abolished when the active site
of the protease was point-mutated and used as a dominant negative. The physiological relevance of these drastic behavioural
changes is discussed.
Introduction
Memory and learning as well as adaptive reorganizations after nervous
system injury critically depend on synaptic plasticity, i.e. the capacity
of synapses to change their structure and function to satisfy particular
functional or adaptive requirements. Recently the role of extracellular
proteolytic processes at the synapse for the regulation of synaptic
structure, function and modiﬁcation has been described (Gottschalk &
Deb, 1996; Lu¨thi et al., 1997; Shimizu et al., 1998; Chan & Mattson,
1999; Komai et al., 2000; Shiosaka & Yoshida, 2000). Serine proteases
(e.g. neurotrypsin and tissue-type plasminogen activator) or inhibitors
(such as neuroserpin) are considered to be involved in plasticity-related
events in the nervous system (Yong et al., 1998).
In a screening for genes induced after drug treatment, we found that
urokinase plasminogen-type activator (uPA) was strongly regulated by
cocaine in several protocols. uPA is an inducible secreted serine
protease found in vertebrates that speciﬁcally converts the inactive
zymogen plasminogen into plasmin, a trypsin-like protease of broad
substrate speciﬁcity (Appella et al., 1981). The plasminogen activation
system has been implicated in multiple events requiring extracellular
proteolysis in blood and tissues, such as blood clot dissolution, cell
migration and invasion, inﬂammation, tissue repair and remodelling,
and embryonic development (Gingrich & Traynelis, 2000; Schwab
et al., 2001; Mustjoki, 2003). uPA is continuously produced in some
tissues or cell types and only transiently in others, where it can be
modulated by diverse effectors such as hormones, cytokines and
growth factors. Accordingly, the uPA gene includes consensus motifs
for the binding of a relatively large group of transcription factors
involved in the transcriptional activation of both inducible and
constitutively expressed genes (Nienaber et al., 2000). uPA associates
with its functional urokinase receptor into a multifunctional system,
involved in tissue remodelling, affecting cell migration and adhesion
and plays a role in vitro nectin- and integrin-mediated cytoskeleton
reorganization (Wang et al., 1998; Wang et al., 2000; Degryse et al.,
2001). In human vascular smooth muscle cells, the complex is
associated with the ecto-protein kinase casein kinase-2 (CK2), which,
via phosphorylation of nucleolin, mediates mitogenic effects of
urokinase and regulates urokinase-dependent cell adhesion to vitro-
nectin (Stepanova et al., 2002).
uPA activity in the brain has been described mainly during
development and is involved in axonal growth or tissue remodelling
associated with neural development (Sumi et al., 1992; Mustjoki,
2003) and in neoplastic and cultured brain cells (Del Bigio et al.,
1999). uPA, its receptor and its inhibitors are expressed in immature
glial and neuronal cells in postnatal mouse forebrain. In the adult mice
brain, uPA mRNA is not abundant but is strongly expressed by many
classes of neurons in the peripheral and central nervous system and in
spinal chord and sensory ganglia (Masos & Miskin, 1996; Miskin &
Masos, 1997). It is localized in neurons in a few speciﬁc areas,
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primarily the subiculum and entorhinal cortex – which anatomically
and functionally are linked to the hippocampus – and it is also found
in the parietal cortex (Masos & Miskin, 1996; Del Bigio et al., 1999).
uPA mRNA increases substantially in the neocortex and limbic
structures upon neuronal activation by kainic acid, a seizure-inducing
agent (Masos & Miskin, 1997), and uPA may be involved in
hippocampal epileptogenesis (Kishi et al., 1999) as well as in brain
tumours (Arai et al., 1998) or blood–brain barrier damage (Nienaber
et al., 2000; Rosenberg et al., 2001).
In this study, we aimed to investigate the physiological function of
uPA in the mesolimbic dopaminergic pathway, a major target area of
cocaine and drugs of misuse. For this purpose a tetracycline-
regulatable lentivirus, expressing uPA (or its mutated, inactive form)
under the control of doxycycline, was prepared. After stereotaxic
injection of the virus into speciﬁc rat brain areas, local expression of
uPA from the lentivirus could be assessed and correlated with massive
behavioural changes induced upon drug treatment. This approach
enables us to switch locally gene expression on ⁄ off and to evaluate in
the same animal how in vivo modulation affects drug-related
behaviour. Drug addiction is a complex neuropsychiatric disorder,
related to aberrant brain function, resulting in a loss of control over
drug-taking or compulsive drug-seeking, despite noxious conse-
quences (Nestler, 2000). Our approach may prove useful for
understanding the molecular basis of this disorder, which requires
the identiﬁcation of molecular candidates and suitable animal models
to investigate the role of speciﬁc genes in mediating the development
of drug addiction.
Experimental procedures
Lentivirus construction of Lenti-uPA-His6 and Lenti-GFP
The rat uPA cDNA (GenBank accession no. X63434) was ampliﬁed
by reverse transcription. Brieﬂy, 2 lg of total RNA [prepared from rat
ventral tegmentum area (VTA) of cocaine-treated animals] was added
to 1 lg Oligo-(dT)12)18, 2 lL of dNTP mix at 10 lm each and made
up to 12 lL with Rnase-free water. These components were mixed
and heated at 65 C for 5 min, then kept on ice. To the mixture, 4 lL
of 5· ﬁrst-strand buffer was added, followed by 2 lL 0.1 m DTT,
10 U RNAsin, and 1 lL of 200 U ⁄ lL Superscript II RNaseH –
Reverse Transcriptase (Invitrogen, Basel, Switzerland). The mixture
was incubated at 42 C for 3 h. To remove RNA–DNA hybrids, 2 U
RNase (H) was added and incubated at 37 C for 30 min. The cDNA
was then PCR ampliﬁed and 6His-tagged with the two following
primers: CGCGGATCCGCATGAGAGTCTGGCTTGCG as forward
primer and CCGCTCGAGCGGTTAATGATGATGATGATGATGA
TTAAGTTAACACTGC as reverse primer. The forward primer
contains a BamHI restriction site (bold) followed by the 5¢ rat uPA
cDNA-speciﬁc sequence, and the reverse primer contains the 3¢ rat
uPA cDNA-speciﬁc sequence, a 6His-Tag (underlined), a stop codon
and an XhoI restriction site (bold). The PCR product was digested with
BamHI and XhoI and cloned into similar sites in pTK431 (Fig. 1A).
The pTK431 is a self-inactivating (SIN) HIV-1 vector, which contains
the entire tet-off inducible system, the cPPT and the woodchuck
hepatitis virus post-transcriptional regulatory element (WPRE) (Bahi
et al., 2004). It was generated by ligating a BglII ⁄ BamHI DNA
fragment containing the tetracycline-regulated transactivator tTA (5¢)
and the tetracycline inducible promoter (3¢) into a BamHI site
downstream to a CMV promoter in an SIN HIV-1 vector. A control
vector construct, pTK433 (Fig. 1A), in which green ﬂuorescent protein
(GFP) expression is regulated by a tetracycline inducible promoter,
was generated by cloning a BamHI ⁄ BglII DNA fragment containing
the GFP gene into a BamHI site in pTK431 (Bahi et al., 2004). All
plasmids were CsCl2 puriﬁed.
Site-directed mutagenesis and construction of Lenti-uPA-Mut
The uPA cDNA sequence was point-mutated in two active site-
composing amino acids, H225G (CAC ﬁ GGC) and S377A
(TCA ﬁ GCA). Mutagenesis was performed with the QuickChange
site-directed mutagenesis kit (Stratagene, Switzerland). The following
oligonucleotides (single-stranded sense and antisense oligonucleo-
tides) were used as primers; (H225 G): 5¢-GGGTGGCCAGCGCCA
CAggCTGCTTCGTGAATCAGCC-3¢ and 5¢-GGCTGATTCACGAA
GCAGccTGTGGCGCTGGCCACCC-3¢; (S377A): 5¢-GCTCGGGA
GATgCAGGAGGACCTCTTATCTGTAACATCG-3¢ and CGATGTT
ACAGATAAGAGGTCCTCCTGcATCTCCCGAGC. PCRs were per-
formed with wild-type pCRII-uPA-His6 cDNA as template, following
the manufacturer’s instructions. The PCR products, digested by DpnI
(Biolabs, Switzerland), were used for transformation and ampliﬁed.
Mutations were veriﬁed by sequencing. The insert was then digested
with BamHI and XhoI and cloned into pTK431 transfer vector. This
construct, pTK431-uPA-Mut, was used for triple transfection and
preparation of lentivirus (Lenti-uPA-Mut).
Lentivirus production
The vector plasmid (either pTK431-uPA-6His, pTK431-uPA-Mut or
pTK433), together with the packaging construct plasmid pDNRF and
the envelope plasmid pMDG-VSVG were co-transfected into
HEK293T cells to produce the Lenti-uPA-His6 or Lenti-GFP viral
particles, respectively, according to previously published procedures
(Naldini et al., 1996; Bahi et al., 2004). High-titre stocks were
obtained by ultracentrifugation at 45 000 g for 2 h at 4 C. The pellet
was resuspended in PBS containing 1% bovine serum albumin, and
stored frozen at )80 C. The viral titres were determined by p24
antigen measurements (KPL, USA). For in vivo experiments, the
different viral stocks matched for viral particle content were used at
0.2 mg ⁄mL of p24, corresponding to 8 · 109 infectious particles ⁄mL.
Microarray design and analysis
Microarray design was performed according to published methods
(Shalon et al., 1996). Brieﬂy, speciﬁc oligos were synthesized with
5¢-amino modiﬁcation and arrayed onto QMT Aldehyde Slides
(Quantifoil, Germany) and stored at room temperature for further
hybridization.
Probe design was according to that of Bahi & Dreyer (2004) and
recommendations by QIAGENTM. Brieﬂy, 70mer probes for ten
negative and ten positive control genes and for uPA were designed
within 1000 bases from the 3¢ end of the available gene sequence;
probes were selected with an optimal set of parameters, sequence
optimized using BLAST for nucleotide sequence to minimize cross-
hybridization in microarray experiments and Tm (melting temperature)
was normalized to 78 C (± 5 C).
The ten negative controls were oligonucleotides randomly
generated with no expression within either the mouse or the rat
genomes. The ten positive controls were oligonucleotides speciﬁc for
b-actin (NM_031144), transcription factor E2a (X17500), lactate
dehydrogenase A (NM_017025), Hsp70-1 (NM_031971), nuclear
pore glycoprotein 62 (M62992), ribophorin 20814 (NM_031698),
ribosomal protein L5 (NM_031099), ribosomal protein S9
(NM_031108), glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
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(NM_017008) and polyubiquitin (D16554). Oligonucleotide
sequences of positive and negative controls are patented (QIAGENTM,
Basel, Switzerland) and are not listed. For uPA the following
oligonucleotide was used: 5¢-TGCAAGTCTAGGTATTTCCCTCC
CTCCAGACTGTGATGCGGCCCATTTGGTCTTCCGTGATGCTC
CACTT-3¢.
For probe preparation, each aRNA sample (one from control
samples and one from treated samples) was reverse-transcribed in the
presence of Cy3-dCTP (control samples) or Cy5-dCTP (treated
samples) and puriﬁed, according to the methods of Bahi & Dreyer
(2004). Before hybridization, the probe solution was boiled for 1 min,
and then rapidly applied to the microarray under a cover slip. Slides
were placed in hybridization chambers and incubated for 14–16 h in a
water bath at 64 C, then washed and dried before scanning with
a scanning laser microscope (Affymetrix 428TM array scanner;
Affymetrix, Inc., Santa Clara, CA, USA).
Separate images were acquired for each ﬂuorochrome at a
resolution of 10 lm per pixel. To normalize the two channels with
respect to signal intensity, photomultiplier and laser power settings
were adjusted such that the signal ratio of the control genes was as
close to 1.0 as possible. The average ﬂuorescence intensity for each
ﬂuorochrome and for each gene was determined using Jaguar 2.0
Fig. 1. (A) Lentivirus constructs. Transfer plasmids pTK431-uPA-6His and pTK433-GFP used in this study for the production of Lenti-uPA-6His and Lenti-GFP.
The plasmids contain a Tet-Off element under the control of a minimal CMV promoter and a cPPT element. (B) Drug administration protocols. Acute treatment:
animals (n ¼ 6) were injected with a single dose of cocaine (15 mg ⁄ kg) and killed 24 h after injection. Binge treatment: animals (n ¼ 6) received four injections of
high-dose cocaine (30 mg ⁄ kg) and were killed 24 h after the last injection. Chronic treatment: animals (n ¼ 6) received a single dose of cocaine (15 mg ⁄ kg) every
day over 15 days and were killed 24 h after the last injection. ‘Behavioural sensitization’ treatment: four groups of animals (n ¼ 6) were used. Initially each group
received daily injections over 5 days of either saline (groups S1 and S2) or cocaine (15 mg ⁄ kg, groups S3 and S4). Three days after the last injection, groups S1 and
S3 were challenged with a single dose of saline (group S1) or cocaine (15 mg ⁄ kg, group S3) and killed 24 h after the injection. Fourteen days after the last injection,
groups S2 and S4 were challenged with a single dose of saline (group S2) or cocaine (15 mg ⁄ kg, group S4) and killed 24 h after the last injection.
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(Affymetrix), which calculates normalized expression levels and ratios
of experimental (Cy5) vs. control (Cy3) signals. Background ﬂuor-
escence was calculated as the median ﬂuorescence signal of non-target
pixels around each gene spot. The means of values of the negative
controls were considered as background and subtracted from all other
data. Positive controls displayed neither up- nor down-regulation in all
samples under investigation and the ratio of experimental vs. control
was almost equal to one in all cases.
Data sets were further statistically analysed and P-values evaluated
using a stringent cut-off for signiﬁcance. Induction or repression of a
gene was deﬁned as a minimum 1.5-fold change in its transcript level.
Genes were considered to be down-regulated if the ratio of experi-
mental to control was 0.12–0.5 (or )0.12 to )0.5) with P < 0.01 or
up-regulated if the ratio of experimental to control was 2 or more with
P < 0.01. Signiﬁcance was calculated using a t-test.
Drug administration protocols for microarray analysis and
quantitative real-time PCR
Animals used in this experiment were male Wistar rats weighing 225–
250 g (BRL, Fu¨llinsdorf, Switzerland). All animal experiments were
carried out in accordance with the guidelines and regulations for
Animal Experimentation, BAG, Bern, Switzerland. The animals were
housed in threes in clear plastic cages with wire grid lids. Access to
food and water was unrestricted. The animals were kept in the animal
facility maintained on a 12-h light : 12-h dark cycle (lights off at
07:00 h). Four different protocols for drug administration were used,
as described in Fig. 1B.
1 Acute Protocol: animals (n ¼ 6) were i.p. injected once with
15 mg ⁄ kg cocaine ⁄HCl (Sigma Chemical Co.).
2 Chronic Protocol: animals (n ¼ 6) were i.p. injected daily with
15 mg ⁄ kg cocaine ⁄HCl for a period of 15 days;
3 Binge Protocol: animals (n ¼ 6) were injected i.p. in total four
times with 30 mg ⁄ kg cocaine ⁄HCl every 2 h.
In all three protocols control animals received a 0.9% saline i.p.
injection instead of drug under the same schedule. Twenty-four hours
after the last injection, animals were killed by decapitation and the
brain area were dissected out and used for isolation of total RNA,
using RiboPure Kit (Ambion, UK) followed by RNA ampliﬁcation
according to previous methods (Kacharmina et al., 1999; Bahi et al.,
2004).
4 Sensitization Protocol: four groups (n ¼ 6 per group) were used,
designated groups S1–S4. Each group was treated with either saline or
cocaine for 5 days, then challenged with either saline or cocaine 3 or
14 days after the last injection, and ﬁnally killed 24 h later after the
challenge by decapitation and the brain area were dissected out and
used for isolation of total RNA followed by RNA ampliﬁcation.
Groups S1 and S2
Animals were treated with daily i.p. injection of 0.9% saline over a
period of 5 days. Group S1 was challenged 3 days after the last
injection with i.p. injection of 0.9% saline, and group S2 was
challenged 14 days after the last injection with i.p. injection of
15 mg ⁄ kg cocaine ⁄HCl.
Groups S3 and S4
Animals were given daily i.p. injection of 15 mg ⁄ kg cocaine ⁄HCl
(Sigma Chemical Co.) over a period of 5 days. Three days after the
last injection group S3 was challenged with i.p. injection of 0.9%
saline daily, and 14 days after the last injection group S4 was
challenged with i.p. injection of 15 mg ⁄ kg cocaine ⁄HCl.
For real-time PCR analysis, total RNA was not ampliﬁed before
PCR performing. See ‘In vitro assays’ for further details concerning
the methodology and oligos used in this study.
Strereotaxic surgery and behavioural analysis
Stereotaxic surgery and injection of the lentiviral vector were
performed according to previously described methods (Bahi et al.,
2004). Male Wistar rats were bilaterally injected into either the VTA,
the NAcc or into the hippocampus with 2 lL of concentrated lentiviral
stock (0.2 mg ⁄mL of p24, corresponding to 8 · 109 IU ⁄mL). The
injections were performed bilaterally at the following coordinates, as
calculated from bregma and the dura mera: (a) in the VTA: anterior )6;
lateral ±0.6; ventral )8; (b) in the NAcc: anterior +1.4; lateral ±1.6;
ventral )6.8; (c) in the ventral subiculum of the hippocampus: at two
different coordinates, designated VSub-1 and VSub-2, with VSub-1:
anterior )5.3; lateral ±4.8; ventral )6.8; and VSub-2: anterior )6;
lateral ±5.3; ventral )4. Following surgery the diet consisted of normal
food pellets soaked in water for 3 days.
One week after surgery, locomotor activity was monitored in MED-
OFA-RS cages (MED Associates Inc., USA) during the dark cycle in
daily sessions over 16 days, according to previously published
procedures (Bahi et al., 2004). The animal was placed in the
activity-monitoring cage for a 30-min baseline recording without drug.
The session was then automatically paused and each subject received
cocaine ⁄HCl (15 mg ⁄ kg, i.p) and was then placed back into the
locomotor activity-monitoring cage for a further 60 min.
Where assessing dose-dependent effects of cocaine on uPA-
mediated changes in locomotor activity, animals were injected with
Lenti-uPA-His6 into the NAcc using the same coordinates as above
and were administered a single i.p. injection of 7, 10, 15 or 30 mg ⁄ kg
of cocaine ⁄HCl.
The activity monitor computed the location of the animal in each of
the X and Y dimensions as the middle point between the extreme
beam interruptions. Speed was estimated by computing standard
deviation of the distances of data points to their mean within a sliding
time window 0.4 s wide. Within the same experimental group, means
and standard deviations were recorded for measurements performed
each day during one session. The t-test was performed by comparison
of the six animals (three from each group) at the same time point and
the P-value was calculated to check for the signiﬁcance of the
difference between the groups with and without doxycycline.
Immunohistochemistry
Rat brains were rapidly removed and frozen in isopentane (at )30 C
for 3 min) and kept at )25 C. Coronal sections were cut at 14 lm in a
cryostat (Leitz), placed on gelatinized glass slides, air-dried at room
temperature for 20 min and kept at )25 C until further processing.
Antigens were localized using the avidin–biotin–peroxidase technique.
Slices were ﬁxed in 4% PFA for 15 min, and washed three times
with 1· PBS. Endogenous peroxidase activity was quenched with 2%
hydrogen peroxide in water (H2O2) for 40 min at room temperature
(RT). Non-speciﬁc binding was blocked for 30 min at RT in 1· PBS
containing 1% bovine serum albumin, 1% Triton X-100 and 3%
normal goat serum. Sections were then rinsed and incubated overnight
with mouse anti-histidine antibody (MCA1396, Serotec, 1 : 12 000)
diluted in 1· PBS containing 1% Triton X-100 and 1% normal goat
serum. Sections were then washed three times with 1· PBS and
incubated with the biotinylated secondary antibody (goat anti-mouse
immunoglobulin G, Vector Laboratories, Burlingame, CA, USA,
4
ht
tp
://
do
c.
re
ro
.c
h
1 : 500) for 45 min at RT. Sections were rinsed three times for 5 min
in 1· PBS at RT, followed by avidin–biotin complex (Vector
Laboratories) in 1· PBS solution. After three rinses in 1· PBS, all
sections were developed in 0.025% 3–3¢ diaminobenzidine tetrahy-
drochloride (DAB) plus 0.02% H2O2 for 10–15 min. Sections were
then dehydrated, mounted in permanent medium (Eukitt) and
examined with a Zeiss light microscope. GFP-expressing sections
were cover-slipped with AF1 mounting solution (Citiﬂuor Ltd), and
directly observed using a multiﬂuorescence Axioplan 2 imaging
microscope (Zeiss, Germany) mounted with a multichannel Axiocam
camera (Zeiss, Germany) combined with Axiovision 3.1 acquisition
software (Zeiss, Germany). In all cases negative controls included
omission or substitution of the primary antibody.
In vitro assays
The efﬁciency of the Lenti-uPA-His6 was tested in vitro by infection
of HEK293T cells: 3 · 105 HEK293T cells were plated per well in
six-well plates. The next day, 1–4 lL from lentiviruses stocks was
mixed with 10 lg ⁄mL Polybrene (Sigma, Buchs, Switzerland)
with ⁄without 30 ng ⁄mL doxycycline (Sigma, Buchs, Switzerland),
incubated for 30 min at RT, added to the cells and incubated at 37 C.
After 24 h the medium was replaced with normal growth medium and
cells were left for a further 24 h. One portion of the cells was used for
total RNA isolation (for real-time PCR) and the remaining part was
used for immunocytochemistry.
Quantitative real-time PCR and quantiﬁcation of uPA mRNA
For quantitative real-time PCR (qRT-PCR), primer sets for rat uPA,
GAPDH and b-actin were designed to amplify 100- to 300-bp
products, using PRIMER3 software (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_http://www.cgi). The following speciﬁc primer pairs
were used:
for rat uPA,
5¢-CAGTCCTTGCGTGTCTGCC-3¢ and
5¢-CGCTGGGCTCTCTCTAGACAG-3¢;
for rat GAPDH,
5¢-ATGACTCTACCCACGGCAAG-3¢ and
5¢-CATACTCAGCACCAGCATCAC-3¢;
for rat b-actin,
5¢-AGCCATGTACGTAGCCATCC-3¢ and
5¢-CTCTCAGCTGTGGTGGTGAA-3¢.
GAPDH and b-actin were used as endogenous controls for
normalization. No difference was observed between these two genes
for all quantiﬁcations.
Total RNA was extracted from the HEK293T cells using RiboPure
Kit (Ambion, UK) including a RNase-free DNase step, and stored at
)80 C. RNA was quantiﬁed by spectrophotometry, and its integrity
veriﬁed by agarose gel electrophoresis as visualized with ethidium
bromide staining. First-strand cDNAwas generated from 1 lg of total
RNA and Oligo(dT12-18) primer with the M-MLV reverse transcription
kit (Invitrogen) in a total volume of 20 lL. The reaction product was
used for qRT-PCR using the real-time PCR iCycler (Bio-Rad,
Reinach, Switzerland). Five microlitres of cDNA preparation,
0.5 lm of forward and reverse primers and 10 lL of IQ SYBR
Green Supermix (Bio-Rad) in a total volume of 20 lL were applied
and PCR was performed as follows: 3 min at 95 C (initial
denaturation); 20 C ⁄ s temperature transition rate up to 95 C for
45 s, 45 s at 62 C, repeated 40 times (ampliﬁcation). The PCR
reaction was evaluated by melting curve analysis and by checking the
PCR products on 2% agarose gel.
The PCR cycle number at which each assay target reached the
threshold detection line was determined (Ct value). cDNA samples
were assayed on at least three dilutions to check for assay reliability
using a duplicate assay on each dilution. The DCt for each candidate
was calculated as DCt ¼ [Ct (candidate) ) Ct (GAPDH or b-actin)].
The relative abundance of each target in each protocol can be
calculated as the ratio between treated and untreated samples
(Mu¨hlbauer et al., 2004).
Immunocytochemistry on HEK293T cells
At the end of the infection period, cells were washed twice with
1· PBS, ﬁxed with prewarmed 4% PFA for 30 min and washed
again with 1· PBS buffer. Cells were blocked for non-speciﬁc
binding with 3% normal goat serum diluted in 1· PBS for 20 min,
washed twice with the same buffer and incubated for 3 h at RT with
mouse anti-histidine-tag antibody (MCA1396, Serotec, 1 : 200) in 1·
PBS containing 1% normal goat serum and 0.1%Triton-X100. Cells
were rinsed three times with 1· PBS and incubated with the
secondary antibody (FITC-conjugated goat anti-mouse immunoglob-
ulin G, Molecular Probes, 1 : 1000) in 1% normal goat serum, 0.1%
Triton-X100 in the dark at RT for 3 h. Cells were washed three times
with 1· PBS and cover slipped with AF1 mounting solution
(Citiﬂuor Ltd). In all cases negative controls included omission or
substitution of the primary antibody. Stained cells were observed
using a multi-ﬂuorescence Axioplan 2 imaging microscope (Zeiss,
Germany) mounted with a multi-channel Axiocam camera
(Zeiss, Germany) combined with Axiovision 3.1 acquisition software
(Zeiss, Germany). The ﬂuorophore was detected with the appropriate
detecting system.
Results
uPA up-regulation in different drug administration protocols
uPA was found initially in a screening for genes up-regulated after
cocaine administration. In order to characterize this observation
further, up-regulation of uPA was conﬁrmed in different protocols of
drug administration, summarized in Fig. 1B, i.e. acute, binge, chronic
and four additional treatments (‘behavioural sensitization’). The acute
protocol corresponds to a single exposure to the drug, as opposed to
the chronic treatment, which was used in all behavioural assays. The
binge protocol mimics the treatments in humans and allows for easy
assessments of neurobiological changes associated with addiction
(Michna et al., 2002). The fourth protocol is an established model of
‘behavioural sensitization’ (Heidbreder et al., 1996), subdivided into
two distinct temporal parts, initiation and expression; based on this
schedule, data have shown that some genes are involved in the latter,
but not in the former phase (Hedou et al., 2002).
uPA-speciﬁc oligonucleotides were spotted on a glass array,
together with positive and negative controls (see Methods). The total
RNA from four different brain regions of animals treated under the
different protocols (Fig. 1B, n ¼ 6) was prepared and hybridized. As
shown in Fig. 2A, uPA was up-regulated in most treatments and in all
regions investigated. In the hippocampus, the up-regulation was
strongest in S3 and S4 groups (i.e. animals treated with cocaine over
5 days and challenged with the drug either after 3 days or after
2 weeks of withdrawal, respectively), whereas a two-fold up-regula-
tion was observed in this region after chronic treatment. In the NAcc,
up-regulation was very strong under all treatments: in groups S3 and
S4 of the ‘behavioural sensitization’ protocol or after chronic
treatment, a 5- to 5.8-fold up-regulation was observed, whereas under
other treatments, we found a ca. four-fold up-regulation, except for
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group S1 (animals initially treated with saline and challenged with
saline after 3 days). In the striatum (caudate putamen) the effects were
similar but weaker, yielding up to ﬁve-fold up-regulation (group S4).
Finally in the VTA very strong up-regulation was observed in group
S4 (> six-fold) and S3, or in binge (four-fold increase in both groups).
In all cases the increase was highly signiﬁcant (P < 0.01). Other brain
Fig. 2.
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regions have not been tested. Under these conditions all control genes
are unaffected.
In order to verify and conﬁrm these data from microarray analysis,
the drug administration protocols were replicated on another set of
animals (n ¼ 6) treated under the same protocols, and total RNA from
the four brain regions were prepared and used for real-time
quantitative PCR. All results from microarray analysis could be fully
conﬁrmed by means of qRT-PCR in all four brain areas using uPA-
speciﬁc oligos, as shown in Fig. 2B. In all cases the changes are again
highly signiﬁcant (P < 0.01).
Following repeated cocaine administrations (‘chronic’ and ‘beha-
vioural sensitization’ protocols) uPA mRNA is up-regulated. This
overexpression is much higher after 14 days of withrawal. mRNA
levels before the challenge times have not been measured (as no
animal were killed just prior to the challenge time); however, the
data presented in this study are from samples of animals killed 24 h
after the last drug administration and therefore the levels of mRNA
are relatively stable for at least 24 h (e.g. in the NAcc six-fold
increase, in the VTA four-fold increase, vs. saline, respectively). By
contrast, even after 3 days of drug removal (group S3) the mRNA
Fig. 2. Microarray and qRT-PCR analysis of uPA expression changes of cocaine-treated animals. (A) Microarray analysis of uPA expression changes in different
brain regions and different drug delivery protocols. Microarrays were prepared as microscope slides as described in the Methods section from speciﬁc 70mer oligos.
Candidates were spotted eight times on a glass microarray, together with controls. Controls included 20 candidates (ten positive and ten negative controls, see
Methods). Animals (n ¼ 6) were injected with cocaine according to the different protocols (Fig. 1). Total RNA from four brain areas, including the tegmentum, the
NAcc, the hippocampus and the dorsal striatum of cocaine-treated and saline-treated animals were prepared, labelled with Cy5-dCTP (cocaine-treated subjects) and
Cy3-dCTP (saline-treated subjects) and hybridized on the microarrays. aRNA preparation and hybridization was performed from three independent tissue samples of
cocaine- or saline-treated animals. Arrays were scanned and analysed as described. (B) qRT-PCR of cocaine-induced uPA transcript changes. Animals (n ¼ 6) were
treated under the same drug administration protocols as in A, killed and dissected. Total RNA from the four brain areas were prepared and reverse transcribed for
qRT-PCR using uPA speciﬁc oligos (see Methods). (C) uPA transcript levels from saline-challenged animals in S3 and S4 schedules (see ‘sensitization’ protocols,
Fig. 1B). After cocaine administration for 5 days followed by saline challenge, respectively 3 and 14 days after the last injection, mRNA levels of groups S3 (short
withdrawal) and S4 (long withdrawal) were compared. Saline challenge had almost no effect on uPA expression and the ratio was equal to 1.0. (D) P-values of
ratios of uPA expression during ‘sensitization’ schedules. uPA expression after initial cocaine delivery (S3 and S4 groups) compared with saline (S1 and S2 groups)
was signiﬁcantly higher, as shown by calculation of the P-values. Hipp: hippocampus, NAcc: nucleus accumbens, CPu: caudate putamen, VTA: ventral tegmentum
area, Short: short withdrawal, Long: long withdrawal, *P < 0.05, **P < 0.01.
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levels reached basal values (Fig. 2C). This indicates that mRNA is
relatively stable for at least 24 h in the chronic protocol used in
behavioural studies, in good correlation with our ﬁndings that
locomotor activity changes were observed within the ﬁrst 30 min
prior to cocaine delivery (see below). In addition, it has been
established that half-life of uPA in cells is about 2 h (Sokabe et al.,
2004).
It is interesting to observe from the ‘behavioural sensitization’
protocols that, when initially treated with cocaine, animals express
more uPA mRNA than when initially treated with saline (Fig. 2D).
This overexpression is highly signiﬁcant in all brain areas tested.
Figure 2D illustrates the difference observed between the various
treatments during the ‘behavioural sensitization’ protocols: S1 vs. S3
and S2 vs. S4 (*P < 0.05, **P < 0.01).
A detailed analysis of microarray and qRT-PCR data further
shows that uPA mRNA is not induced when animals were
challenged with saline, even after repeated cocaine injections, and
mRNA levels are not affected after a short or even long withdrawal
period (3 vs. 14 days). As shown in Fig. 2C, the ratios of
uPA ⁄GAPDH are almost equal to 1.0 in all cases. The same results
were observed when normalization was performed against b-actin
(data not shown). There seems to be no conditioned induction of
uPA mRNA levels when rats are challenged with saline following
repeated cocaine administrations.
In vitro assay of lentivirus-mediated uPA expression
in HEK293T cells
uPA was cloned into a tetracycline-regulatable lentivirus system and
the lentivirus expressing uPA (Lenti-uPA-His6) was used for in vitro
assays (see Methods). HEK293T cells were infected with different
amounts of virus (Fig. 3A) and uPA mRNA was measured by qRT-
PCR. As shown, Lenti-uPA-His6 increases the uPA transcripts and
protein in a dose (titre)-dependent way. Using 1 lL of the viral stock,
uPA mRNA increases by 1.5-fold; this reaches two-fold using 2 lL of
viruses. Finally, a four-fold increase in uPA mRNAwas observed with
4 lL. This increase is completely reversible using doxycycline, which
blocks uPA expression, both at the mRNA and at the protein levels
(Fig. 3A and B). For real-time PCR, uPA transcripts levels were
normalized against both GAPDH and b-actin used as endogenous
controls. No difference was observed between these two genes (data
not shown).
Behavioural changes induced by local expression of wild-type
and mutated forms of uPA using regulatable lentiviruses in vivo
Lentivirus expressing either wild-type uPA (Lenti-uPA-His6), its
mutated form (Lenti-uPA-Mut) or GFP (Lenti-GFP, as a control) was
stereotaxically inoculated into animals in three speciﬁc brain areas, the
Fig. 3. In vitro expression of Lenti-uPA-His6 in HEK293T cells. (A) Quantiﬁcation of uPA expression by means of qRT-PCR. Using polybrene protocol (see
Methods), HEK293T cells were infected with 1, 2 or 4 lL of the Lenti-uPA-His6 lentiviruses expressing uPA-His6 in culture medium with ⁄without doxycycline
(30 ng ⁄mL). After 48 h, culture medium was removed, one part of the cells was used for total RNA extraction, cDNA preparation and qRT-PCR using uPA-speciﬁc
oligos; results were normalized against GAPDH and b-actin genes used as endogenous controls. (B) Immunocytochemistry after HEK293T cells infected with
Lenti-uPA-His6. The remaining cells infected with 4 lL of Lenti-uPA-His6 were used for ﬂuorescence microscopy using a mouse histidine-tag antibody to check for
uPA-His6 protein expression and regulation by doxycycline (30 ng ⁄mL). *P < 0.05; **P < 0.01; ***P < 0.001.
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NAcc, the VTA or the VSub (see Methods). After 7 days of recovery
under normal feeding conditions (no doxycycline), animals were
administered cocaine under a chronic protocol (single daily injection
of 15 mg ⁄ kg) in the absence of doxycycline, enabling full expression
of uPA (or GFP in control animals) in the infected brain area, and
locomotor activity was assessed. Drug administration was performed
30 min after the animal had been placed in the behavioural cage (after
the habituation period); therefore, locomotor activity measured during
the initial 30 min shows the animal’s activity in the absence of drug,
as an internal control. As can be observed in this initial stage (Figs 4–
6), expression of uPA, uPA-Mut or GFP did not affect this basal
activity in the absence of drug. After drug administration (at 30 min) a
strong increase in activity was observed in all animal groups, with a
peak at 40–45 min.
Animals treated with GFP-expressing virus (control virus) dis-
played a maximal peak intensity of ca. 3000 mm at 40 min (distance
travelled per minute, Fig. 4). By contrast, animals expressing wild-
type uPA display locomotor activity peaks 10–12-fold stronger and
delayed by ca. 5 min (Fig. 5). This delay is also observed in animals
expressing the mutated uPA. This delay in maximal activity may well
reﬂect the fact that cocaine induces uPA translation from already
accumulated mRNA and that it is this increase in uPA protein that
affects locomotor activity when the drug is delivered. We believe that
in these repeated cocaine administration protocols uPA is translated
rapidly every time after cocaine injection. Obviously the half-life of
the protein has no incidence on locomotion responses because drug-
induced effects are very fast (within 15–60 min). In addition, the
effects only occur when animals are receiving drug, as a single
injection daily, before monitoring their behaviour. The intensity of
the response is dependent upon the brain area. With animals
expressing wild-type uPA in the NAcc, the maximal peak intensity at
45 min was about 29 000 mm (Fig. 5, initial sessions without doxy);
also the peak intensity increased each day, displaying a maximal
activity after about 5 days of chronic drug administration. The
observed behavioural changes were highest in animals overexpress-
ing wild-type uPA in the VTA (Fig. 5), with a maximum of
ca. 35 000 mm (peak at 45 min at day 5), i.e. a 12.3-fold higher
locomotor activity than control animals was observed under these
conditions. By contrast, when uPA was expressed in the VSub of the
hippocampus, a very strong increase in locomotor activity, of similar
magnitude (about 12.1-fold increase over GFP-expressing control
animals) was also observed (Figs 4 and 5). Two different areas of the
hippocampus had been targeted, designated VSub-1 and VSub-2, based
on previous data indicating that these areas regulate dopaminergic
activity in the ventral tegmental areas (Legault et al., 2000; Floresco
et al., 2001). Overexpression of uPA in any of these two targeted
hippocampal areas induced a comparable magnitude of changes in
locomotor activity.
After 5 days of chronic cocaine administration in the absence of
doxycycline, all animals were fed with 0.02% doxycycline in their
drinking water, enabling down-regulation of uPA and GFP expression.
As shown in Fig. 4, doxycycline had no effects on control animals
injected with GFP-expressing virus: no change in locomotor activity
upon cocaine administration was observed in these animals during the
doxycycline period, as compared with the previous days. By contrast,
animals treated with virus expressing wild-type uPA- displayed very
strong but rapidly decreasing locomotor activity after 4 days of
doxycycline administration (Fig. 5). This drop in activity was
observed for all uPA-expressing animals, irrespective to the brain
area involved. This effect was followed in more detail immediately
after switching the regimen (day 5, 2 to 18 h after regimen change) for
animals expressing uPA in the NAcc and in the VTA: as shown in
Fig. 5, the drop in activity was very rapid during this initial period
(day 5 + 2 h to day 6).
Four days later, the locomotor activity had stabilized to low levels
in all groups. This stage correlates with suppression of uPA
overexpression in these brain areas. Then doxycycline was removed
from the regimen, enabling re-expression of wild-type uPA (or of GFP
in control animals, Fig. 4) in the lentivirus-infected brain areas.
As shown in Fig. 5 (second period without doxycycline), uPA
re-expression induced a progressive increase in locomotor activity that
again progressively reached highest levels (similar in magnitude to
those observed initially at day 3 during the ﬁrst period) before
doxycycline addition. However, no such change was observed over
that period in control animals upon re-expression of GFP (Fig. 4);
locomotor activity remained unaffected throughout the experimental
period in these animals.
The in vivo effects of uPA were then further evaluated using its
mutated form. This should act as a dominant negative, thus interfering
with endogenous uPA that is induced upon cocaine treatment.
Therefore it is expected that upon expression of mutated uPA,
behavioural changes would be reduced over controls (GFP-expressing
animals), because the mutated uPA would compete with the endog-
enous protein for binding to the uPA receptor. Indeed this hypothesis
was conﬁrmed (Fig. 6): in the absence of doxycycline, locomotor
activity was decreased by 40% over control animals (2500 vs.
4000 mm ⁄min); but when doxycycline was added to drinking water,
which would down-regulate lentiviral-mediated expression of the
mutated uPA, while the endogenous wild-type uPA remained induced
by cocaine administration, the distance travelled ( 4000 mm ⁄min)
immediately increases after regimen switch and matches the levels
observed with the control GFP-infected animals (Fig. 6).
To evaluate the effects of cocaine doses on locomotor activity,
animals (n ¼ 6) were injected in the NAcc with lenti-uPA (expressing
the wild-type form of uPA) and behavioural changes were assessed.
As shown in Fig. 7, the increase in locomotor activity after cocaine
administration is dose dependent: in the absence of doxycycline,
administration of 7 mg ⁄ kg of cocaine results in a peak of
12 000 mm ⁄min at 45 min, which increases dose-dependently up to
19 000 mm ⁄min at 30 mg ⁄ kg. Animals fed doxycycline also display
dose-dependent changes in locomotor activity, but the levels are much
lower in each case, as expected, and are similar to levels from control
animals (injected with Lenti-GFP).
Immunohistochemistry conﬁrmed that the observed behavioural
changes in activity corroborate with the levels of uPA re-expression in
the treated brain areas (Fig. 8). At experimental day 5, i.e. immediately
before addition of doxycycline, sets of animals (n ¼ 3) were killed,
and the brains were removed and used for immunohistochemistry to
check for the expression of uPA or GFP, whereas the rest of the
animals received doxycycline and were used for further behavioural
analysis. As shown in Fig. 8, full expression of uPA or GFP was
maintained in all brain areas under investigation throughout this ﬁrst
period. This is in agreement with previous observations (Bahi et al.,
2004) and the fact that lentiviruses are known to infect host cells
permanently, as retroviruses incorporate their genome into the host
genome. At day 9, i.e. immediately prior to removing doxycycline to
the rest of the animals, a further set of animals (n ¼ 3) treated with
lenti-uPA was killed and gene expression was evaluated on these
brains from doxycycline-fed, lenti-uPA-treated animals: immunohist-
ochemistry revealed no signiﬁcant detection of uPA in the injection
sites in all brain regions (Fig. 8). Finally, at the end of the experimental
period, i.e. at day 17, a set of lenti-uPA-treated animals was killed and
gene expression evaluated again by means of immunohistochemistry:
full gene expression of uPA was observed in the target areas (Fig. 8).
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This demonstrates that lentivirus-mediated overexpression in the
absence of doxycycline lasted throughout the experimental period. As
behavioural activity was drastically changed depending upon uPA but
was not affected by changes in GFP expression, these data together
with the effects observed with the dominant negative form of uPA
clearly show that uPA strongly modulates behavioural activity upon
chronic cocaine exposure.
Discussion
This study was prompted after we identiﬁed uPA from a screening
for genes up-regulated after cocaine treatment. In the present study
we conﬁrm the up-regulation of uPA in several brain regions and in
different protocols of cocaine administration. Three independent
approaches fully conﬁrm cocaine-mediated uPA up-regulation:
microarray screening of ca. 5000 rat genes (data not shown),
microarray analysis of uPA-speciﬁc oligonucleotides under 28
different conditions (regions ⁄ protocols) and qRT-PCR of a replicate
set of experiments under the same 28 different conditions, which
perfectly matches previous data. Together, this ﬁrmly establishes a
role of uPA in response to cocaine, an observation that was further
consolidated in this study by means of monitoring behavioural
changes after local injection of a regulatable uPA-expressing
lentivirus. Impressive changes in locomotor activity during chronic
cocaine administration were reproducibly observed: up to a 12-fold
increase in correlation with uPA expression. Up-regulation was
greatest in the mesolimbic dopaminergic pathway, a brain region
efﬁciently activated upon administration of drugs of misuse. Such
drugs involve profound synaptic rearrangements and plasticity, as a
basic mechanism for reinforcement. The regulatable lentivirus system
developed for this study enables efﬁcient switch in local gene
expression, which induces a parallel switch in locomotor activity in a
highly reproducible way.
In this study we found that cocaine treatment enhances uPA gene
expression and that uPA overexpression further augments the inﬂu-
ence of cocaine on animal behaviour. Surprisingly, uPA up-regulation
has no effect without cocaine. This strongly suggests that uPA
constitutes a limiting factor in the capacity of cocaine to stimulate
Fig. 6. Effects of mutated form of uPA expression in the NAcc, VTA and VSub on locomotor activity. Lenti-uPA-Mut was injected bilaterally into the NAcc, VTA
and VSub1 in the co-ordinates speciﬁed in Fig. 4. Seven days after surgery, behavioural tests were performed. Over 5 days, animals were fed without doxycycline,
yielding to full overexpression of mutated uPA in the injected brain areas. On day 5 animals were fed with doxycycline and behavioural activity was measured after
cocaine delivery every day as indicated for ﬁve consecutive days under the same regimen (days 6–10). Right panels display maximum daily intensities of locomotor
activity measured every 45 min.
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locomotor activity. The mechanisms remains to be further elucidated,
but some hypotheses may be discussed.
Reversible nature of the uPA effect – groups of genes induced
after cocaine and mechanisms
The reversible nature of the uPA effect, as shown in Figs 4–6,
indicates that in order to be effective, uPA should be constantly
present. This raises the possibility that uPA exerts its effect through an
aproteolytically independent mechanism, e.g. attachment–detachment
by means of its interaction with its receptor uPAR. The role of uPA in
the brain for plasmin activation is not clear. However, a recent study
has shown that the tissue plasminogen activator–plasmin system
participates in the rewarding effect of morphine by regulating
dopamine release (Nagai et al., 2004). This ﬁnding fully correlates
with the observation described in this paper with cocaine. Together,
this indicates that the plasmin system may play a central role in drug-
induced plasticity.
Plasminogen production in brain is at least 103-fold lower than in
liver and thus uPA-mediated proteolytic cascade is unlikely to be of
major signiﬁcance (Davies et al., 1998). Upon binding to its receptor,
the uPA–uPAR complex serves as co-receptor for various integrins
and may directly bind to the matrix-associated integrin-ligand
vitronectin. Such uPAR-dependent interactions are relevant for
synaptic rearrangement, spine morphology, long-term potentiation
and also for kindling formation in adult brain (Yoshida & Shiosaka,
1999). The interaction can be blocked by the plasminogen activator
inhibitor-1 (PAI-1), a uPA endogenous inhibitor (Zhou et al., 2003). A
balanced level of uPA and PAI-1 is required alternately to disrupt and
re-form interactions of vitronectin with uPAR and regulate integrin
signalling. Therefore, drug-induced uPA expression may be implied in
regulation of integrin signalling. This hypothesis supports observa-
tions describing drug-mediated induction of other surface proteins,
which also act through integrins and mediate synaptic plasticity. For
example, the integrin-binding tetraspannin CD81 (Brenz-Verca et al.,
2001; Michna et al., 2002; Bahi et al., 2004) is strongly induced by
cocaine. Furthermore, Ephrin-B1 and Ephrin-A, which both regulate
integrin function (Davy & Robbins, 2000), and also several
semaphorins with integrin-binding motifs, such as Sema3C, Sema4G
and Sema7A (Pasterkamp et al., 2003), are 4–12-fold regulated upon
cocaine (Bahi & Dreyer, 2004).
Role of hippocampal activation on accumbal dopamine
In this study we have shown that local uPA overexpression within the
dopaminergic mesolimbic pathway induces very drastic changes in
behaviour after cocaine administration, resulting in an up to 12-fold
increase in locomotor activity. The effect was very strong when the
gene was expressed into the VTA directly. But an effect of similar
intensity was reached when the gene was expressed into the ventral
subiculum region of the hippocampus. This agrees with our micro-
array data, which showed that all protocols of cocaine administration
induced a strong up-regulation in the hippocampus, similar to the
up-regulation observed in mesolimbic dopaminergic areas.
Several studies have reported that the ventral hippocampus elevates
nucleus accumbens dopamine by activating dopaminergic neurons of
the ventral tegmental area (Blaha et al., 1997; Legault et al., 2000;
Floresco et al., 2001). The nucleus accumbens is a central component
of basal ganglia and integrates signals arising from cortical and limbic
areas to modulate motor output (Mogenson et al., 1993). Dopamin-
ergic projections from the ventral tegmental area to the nucleus
accumbens septi are involved in investigatory behaviours evoked
by novel stimuli. They are related to the reinforcement of adaptive
investigatory approaches evoked by natural rewards or by rewards
invoked by habit-forming drugs and drugs of misuse (Wise &
Rompre´, 1989; Wise, 1996; Schultz, 1998). Reinforcement and
environmental memory play key roles in addiction and many studies
have stressed the role of the hippocampus in relation to the action of
drugs of misuse, by modulating dopaminergic transmission and
increasing accumbal dopamine through glutamatergic impulse on the
VTA (Floresco et al., 2001; Legault et al., 2000). Excitatory
glutamatergic inputs to the nucleus accumbens arise from ventral
subiculum spiny neurons, which are in close apposition to dopam-
inergic projections arising from the ventral tegmental area (Legault
et al., 2000). There are several projection pathways that can
potentially mediate subicular regulation of dopaminergic cell ﬁring
(see, for example, Floresco et al., 2001, for a discussion) and therefore
several subsites of the subiculum may act in activating dopaminergic
neurons on the ventral tegmental area. For this reason, we have
targeted two different subicular regions with our regulatable lentivirus,
choosing coordinates VSub-1 and VSub-2 from other studies (Legault
et al., 2000; Floresco et al., 2001). Our in vivo study fully conﬁrms
their data and further establishes the role of hippocamal stimulation
in very efﬁciently modulating addiction-related behaviours, at
Fig. 7. Effects of cocaine doses and uPA expression in the NAcc on locomotor activity. Lenti-uPA-6His was injected bilaterally into the NAcc using the
co-ordinates speciﬁed in Fig. 4. Seven days after operation, behavioural tests were performed. Over 5 days, animals are fed without doxycycline, yielding to full
overexpression of uPA in the injected brain area and locomotor activity was monitored after cocaine injection. Each group was injected with different doses of
cocaine: 7, 10, 15 or 30 mg ⁄ kg. On day 5 animals were fed with doxycycline and the behavioural activity was measured using the same drug regimen delivery as in
the ﬁrst period. Right panel displays maximum daily intensities of the locomotor activity measured every 45 min. Each data point represents the average of three
animals.
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magnitudes similar to those reached by direct stimulation of the
nucleus accumbens dopamine release.
Implication for addiction
The neural pathways involved in addiction are still poorly known and
the role of cortical and hippocampal pathways in mediating
reinforcement are still under investigation. Dysfunction of the
dopaminergic system has long been implicated as a primary factor
in the pathophysiology of addiction, which involves strong plasticity
of the mesolimbic dopaminergic pathway. A role of extracellular
proteases in synaptic rearrangement is now well established. From the
present study, uPA is clearly induced upon chronic drug intake, and,
because of its known implication in excitotoxicity (Masos & Miskin,
1997; Kishi et al., 1999), a role of uPA in drug-induced epileptogen-
esis may be possible. On the other hand, drug-mediated uPA
expression may also promote neuronal death, associated in some
cases with chronic drug intake, by means of plasmin-catalysed
degradation of laminin (Chen & Strickland, 1997). Furthermore, our
data show that uPA is a very strong potential candidate in modulating
mesolimbic dopaminergic pathways and alteration of neural circuits
crucial to addiction-related processes. The effects are speciﬁc because,
for example, GFP overexpression does not show any such effect, and
they are reversible because decreasing uPA expression in speciﬁc
brain areas restores drug-related behaviour almost back to normal. To
clarify these effects, the doxycycline-regulatable lentivirus used in the
Fig. 8. Immunohistochemistry of uPA and GFP expression in the NAcc, VTA and VSub after in vivo transfer of either lenti-uPA-6His or lenti-GFP. For uPA
expression: 2 lL of lenti-uPA-6His was injected into the NAcc, VTA and VSub according to the coordinates described in the Methods section. Animals were
given either 5% sucrose or 5% sucrose ⁄ 0.02% doxycycline. Animals were killed at the end of each period (at day 5, before addition of doxycycline for NAcc
and VTA injected groups) ‘–Doxy’, at day 9 (before removal of doxycycline for NAcc and VTA injected groups) ‘+ Doxy’ and at day 17 (day 15 for animals
injected in the VSub) ‘–Doxy’. For GFP expression (Control animals): 2 lL of lenti-GFP was injected into the NAcc, VTA and VSub according to the
coordinates described in the Methods section. Animals were killed in the end of the second doxycycline-free period (–Doxy). All brains were dissected out, and
processed for immunohistochemistry (see Materials and methods ). For each region and period; upper panels: magniﬁcation ·2.5, lower panels: magniﬁcation
·40.
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present study proved to be an ideal tool for assessing the role of uPA
in vivo and its putative function in addiction.
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